STAT3 and Familial prostate cancer: Importantly, in recent years antibodies (e.g., siltuximab) targeting the IL-6/JAK/STAT3 pathway have been tested as monotherapy or in combination with cytotoxic drugs in various clinical trials for treatment of cancers, including prostate cancer (119, 140–142).